Can-Fite BioPharma Ltd. CANF 深 滬
已收盤 10-31 16:00:00 美东时间
0.4226
-0.007
-1.61%
華盛通- 最 高0.435
- 今 開0.423
- 成交量 15.19万股
- 最 低 0.4151
- 昨 收 0.4295
- 總市值 544.19万
- 52周最高 2.35
- 市盈率 靜 --
- 換手率 1.18%
- 52周最低 0.4151
- 委 比 0.00%
- 總股本 1287.72万
- 歷史最高 1419.00
- 量 比 0.99
- 振 幅 4.63%
- 歷史最低 0.4151
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SciSparc (NASDAQ:SPRC) stock increased by 40.8% to $6.28 during Tuesda...
09-30 20:09
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.
09-16 19:03
Can-Fite BioPharma Announces Breakthrough in Liver Disease Treatment with Namodenoson
The latest update is out from Can-Fite BioPharma ( ($CANF) ). On September 15, ...
09-15 19:28
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
Can-Fite BioPharma Ltd. announces a significant clinical finding under its compassionate use program for Namodenoson in treating decompensated liver cirrhosis. A patient experienced complete resolution of esophageal varices, a severe complication of advanced liver disease, following Namodenoson therapy, as confirmed by endoscopic evaluation. This outcome suggests a potential disease-modifying effect of Namodenoson. Prof. Ohad Etzion, a leading ga...
09-15 11:00
Can-Fite Reports H1 2025 Financial Results and Clinical Update
Can-Fite BioPharma Ltd. reported H1 2025 financial results and clinical updates. Namodenoson achieved over 50% enrollment in its pancreatic cancer Phase 2a study and received FDA Orphan Drug Designation. Piclidenoson showed promising results in a UCLA study for vascular dementia. Revenues decreased 36% to $0.20 million. R&D expenses rose 5.16% to $3.03 million, while general and administrative expenses increased 35.47% to $2.07 million. Net loss ...
08-28 12:47
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ModivCare (NASDAQ:MODV) stock increased by 69.6% to $0.95 during Frida...
08-22 20:08
Can-Fite BioPharma Achieves Enrollment Milestone in Pancreatic Cancer Trial
Can-Fite BioPharma ( ($CANF) ) has shared an announcement. On July 30, 2025, Ca...
07-30 19:27
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite BioPharma Ltd. announced over 50% enrollment in Namodenoson's Phase 2a pancreatic cancer trial, highlighting its favorable safety profile and anti-tumor activity. Namodenoson, an A3AR agonist, is being evaluated for safety, clinical activity, and pharmacokinetics in advanced pancreatic adenocarcinoma patients. The study is led by Prof. Salomon Stemmer and reflects strong interest in exploring Namodenoson as a potential treatment for panc...
07-30 11:04
Can-Fite Prices $5M Public Offering Of 8.33M ADSs At $0.60/ADS, Plus Warrants To Purchase 16.67M ADSs For Up To $10M More
Can-Fite BioPharma Ltd.
07-29 00:28
